This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-15. Anything still debated is marked as such rather than presented as settled.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
| Property | Value | Notes |
|---|---|---|
| Molar mass | approximately 4813 Da | calculated from the 39-residue sequence |
| Appearance | white to off-white powder | typical of lyophilised peptide material |
| Solubility class | freely soluble in water | measured value depends on salt form and pH |
| Plasma protein binding | >99 percent | linked to the fatty diacid side chain |
| Class | dual GIP and GLP-1 receptor agonist | receptor activity varies with the assay used |
The peptide shares degradation routes common to modified peptides: deamidation of asparagine and glutamine residues, oxidation of methionine, and backbone hydrolysis under extreme pH. Lyophilized material is generally more stable than a solution, and residual water content directly affects the rate of hydrolysis. In liquid form, aggregation and visible particles can appear after agitation or repeated freeze-thaw cycles. Stability studies therefore track monomer content, aggregate content, and potency over months under defined temperature and humidity.
Cold-chain handling is standard for formulated product, with dry powder stored frozen and ready-to-use solutions refrigerated. Light exposure is minimized because photodegradation of certain amino acid side chains is possible. Shipping and temperature-excursion studies are used to establish whether short deviations affect quality attributes. Documentation supplied with research material usually includes a certificate of analysis listing purity, identity confirmation, and water or residual solvent content. Users are expected to confirm that material meets the stated specification before use.
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
==== Officer of the Order of the British Empire (OBE) ==== Military Division Royal Navy Commander Peter David Ambrose. Commander Charles Anthony Johnstone-Burt. Major Stephen John Duyland Bush, Royal Marines. Commander Michael John Channon. Commander Brian Paul Boxall-Hunt. Commander George McAleese. Commander Peter John Linstead-Smith. Army Lieutenant Colonel Peter John Barrett (482686), Adjutant General's Corps (SPS). Lieutenant Colonel Brian McDonnell (509404), The Royal Anglian Regiment. Lieutenant Colonel George McGarr (508552), The Royal Logistic Corps. Lieutenant Colonel Brian Nutt (489575), Corps of Royal Electrical and Mechanical Engineers. Lieutenant Colonel Keith Henry Neville Prentice (488202), Royal Regiment of Artillery. Acting Colonel John David Reason (467319), Devonshire Army Cadet Force, Territorial Army. Lieutenant Colonel John David Sainsbury, , (453727), Royal Regiment of Artillery (Volunteers), Territorial Army. Lieutenant Colonel John Alexander Broome Salmon (486736), The Princess of Wales's Royal Regiment. Lieutenant Colonel John Alexander Thomson (496402) The Cheshire Regiment (Volunteers), Territorial Army. Lieutenant Colonel Philip Roy West (485857), Royal Regiment of Artillery. Royal Air Force Wing Commander Michael Carl Barter (8026633). Wing Commander Walter Simon Erskine Crum (0608265). Wing Commander Nigel Kenneth Gillingham (5203514). Wing Commander Malcolm Kenneth Hinder (0207878), Royal Air Force Volunteer Reserve (Training). Wing Commander Michael John Jones (0685361). Wing Commander Brian David Longman (0609376).
While smoking caused a significantly lower birth weight, most of the babies born to the smoking mothers were more or less healthy, while the babies with comparable weight born to the non-smoking mothers had congenital diseases, which increased their mortality rate.
==== Alanine ==== The ammonia produced in neurons is fixed into α-ketoglutarate by the glutamate-dehydrogenase reaction to form glutamate, then transaminated by alanine aminotransferase into lactate-derived pyruvate to form alanine, which is exported to astrocytes. In the astrocytes, this process is then reversed, and lactate is transported in the other direction.
== Preservation == Organic compounds originally in living organisms can be preserved in the rock record if certain requirements are met. Proper preservation requires ample supply of organic material, high burial of that organic matter, and that the organic matter is then polymerized and not degraded. The more degraded a biomolecule is the less specific of a biomarker it becomes, as multiple molecules may have the same hydrocarbon skeleton after diagenesis. However, polar terpenoids such as sugiol may be preserved in their unaltered forms in fossil conifers, potentially due to plant resins that protect them from degradation. In samples obtained from a Pliocene fossilized forest most molecules had been significantly degraded, but phenolic abietanes including sugiol remained intact and identifiable. Even in samples that had been approximately 37.7% decomposed as determined by comparing cellulose content, trace amounts of sugiol and more than 10% ferruginol were detected via GC/MS. Sugiol will remain detectable in a sample long after it has lost its anatomical identifiers, making it extremely useful in identifying extremely old or decomposed plant fossils. In a study of preserved fossil wood and buried samples from a middle Jurassic forest located in Poland, a negative correlation was observed between the preservation of anatomical features of the plant samples versus the chemical features.
== Profibrillin cleavage and asprosin secretion == The asprosin mechanism begins with the cleavage of profibrillin-1. While the specific cellular location of profibrillin-1 cleavage is largely unknown, it is speculated to occur between the trans-Golgi network and the cell surface, or upon fibrillin-1 secretion. Furin cleaves asprosin at the R-C-K/R-R motif in the C-terminal domain. This cleavage event is important because it is required for the incorporation of fibrillin-1 into the extracellular matrix. Since furin is expressed in a plethora of cell lines and tissues, the presence or lack of this enzyme does not narrow down the possible locations of asprosin secretion. Evidence suggests that asprosin is secreted from white adipose tissue, which accounts for 5–50% of human body weight and is already known to secrete adipokines such as leptin and adiponectin. While FBN1 is expressed in many tissues, its highest expression in both humans and mice is in white adipose. However, since FBN1 (and thus, asprosin) is widely expressed in many human tissues, it is likely that white adipose is not the only source of plasma asprosin. There has been evidence connecting asprosin secretion from wild-type human dermal fibroblasts suggesting that it may be secreted from skin. It was also discovered that MIN6 pancreatic β-cells and human primary islets containing β-cells secrete asprosin and that secretion is induced by palmitate in a dose-dependent manner. Asprosin has also been detected in saliva samples.
Sources: en.wikipedia.org
Nevertheless, phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase, the well-studied tumor suppressor that is better known as PTEN, gets its name from homology with PTPs and tensin 1. More detailed structure comparisons have revealed that tensins 1-3, PTEN, auxilin and other proteins in animals, plants and fungi comprise a PTP-C2 superdomain. An integrated PTP domain and C2 domain, the PTP-C2 superdomain came into existence over 1 billion years ago and has functioned as a single heritable unit since then. The first tensin cDNA sequence was isolated from chicken. Analysis of knockout mice has demonstrated critical roles of tensin in renal function, muscle regeneration, and cell migration. Evidence is now emerging to suggest tensin is an important component linking the ECM, the actin cytoskeleton, and signal transduction. Therefore, tensin and its downstream signaling molecules may be targets for therapeutic interventions in renal disease, wound healing and cancer.
The enzyme uses the cofactor, reduced nicotinamide adenine dinucleotide phosphate (NADPH). This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3-oxo-5alpha-steroid:NADP+ Delta4-oxidoreductase. Other names in common use include testosterone Delta4-5alpha-reductase, steroid 5alpha-reductase, 3-oxosteroid Delta4-dehydrogenase, 5alpha-reductase, steroid 5alpha-hydrogenase, 3-oxosteroid 5alpha-reductase, testosterone Delta4-hydrogenase, 4-ene-3-oxosteroid 5alpha-reductase, reduced nicotinamide adenine dinucleotide, phosphate:Delta4-3-ketosteroid 5alpha-oxidoreductase, 4-ene-5alpha-reductase, Delta4-3-ketosteroid 5alpha-oxidoreductase, cholest-4-en-3-one 5alpha-reductase, and testosterone 5alpha-reductase.
Great strides were made, however, in the areas of employment (which became nearly full), universal public education (which nearly eradicated adult illiteracy), health care and recreational amenities. Many historic sites, including the central districts of Warsaw and Gdańsk, both devastated during the war, were rebuilt at great cost. The communist industrialization program led to increased urbanization and educational and career opportunities for the intended beneficiaries of the social transformation, along the lines of the peasants-workers-working intelligentsia paradigm. The most significant improvement was accomplished in the lives of Polish peasants, many of whom were able to leave their impoverished and overcrowded village communities for better conditions in urban centers. Those who stayed behind took advantage of the implementation of the 1944 land reform decree of the Polish Committee of National Liberation, which terminated the antiquated but widespread parafeudal socioeconomic relations in Poland. The Stalinist attempts at establishing collective farms generally failed. Due to urbanization, the national percentage of the rural population decreased in communist Poland by about 50%. A majority of Poland's residents of cities and towns still live in apartment blocks built during the communist era, in part to accommodate migrants from rural areas.
Whether or not realists got the Cold War right, they have most certainly got the warm peace wrong. A decade after the Berlin Wall collapsed… their dark vision of the future has not come to pass. The United States remains the world’s only superpower; unipolarity was not a fleeting moment ... Most importantly, despite its continued predominance and political activism, and the first rumbling of international opposition in response to missteps in Kosovo, no coalition has emerged to balance against it … [T]he United States today defies the supposedly immutable laws of realpolitik".
Sources: en.wikipedia.org
It is a synthetic peptide of 39 amino acids bearing a lipid side chain. Its size and architecture place it outside the small-molecule class, and laboratories generally handle it with the precautions used for biologic-like molecules.
The fatty diacid side chain promotes strong binding to serum albumin, which slows clearance and yields a half-life of roughly five days. That profile supports once-weekly administration in clinical use.
In vitro assays detect activity at both the GIP and GLP-1 receptors, but the activity ratio depends on the assay system and the signalling pathway measured. The relative contribution of each receptor to clinical effects is still being characterised.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.